Erythro-9-(2-hydroxy-3-nonyl)hypoxanthine | 95273-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Erythro-9-(2-hydroxy-3-nonyl)hypoxanthine
• 英文别名: 9-[(2S,3R)-2-hydroxynonan-3-yl]-1H-purin-6-one
• CAS: 95273-61-3
• 化学式: C₁₄H₂₂N₄O₂
• 分子量: 278.354
• InChiKey: RSMDQPNZAPMDJC-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  79.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Erythro-9-(2-hydroxy-3-nonyl)hypoxanthine 、 乙酸酐 生成 [(2S,3R)-3-(6-oxo-3H-purin-9-yl)nonan-2-yl] acetate
  参考文献：
  名称：

  SIMON, L. N.;GINER-SOROLLA, A.;GUTTAG, A.

  摘要：

  DOI：
• 作为产物：
  描述：

  1-壬烯-3-醇 在 titanium(IV) isopropylate 、 lithium aluminium tetrahydride 、 L-(+)-酒石酸二异丙酯 、 水 作用下， 以 various solvent(s) 为溶剂， 反应 18.0h， 生成 Erythro-9-(2-hydroxy-3-nonyl)hypoxanthine
  参考文献：
  名称：

  Enantiospecific synthesis of the immunopotentiators erythro-9 (2-hydroxy-3-nonyl) hypoxanthines and the threo-diastereomers.

  摘要：

  DOI：

  10.1016/s0040-4039(01)81715-9

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Esters of hydroxylalkyl-purines, processes for preparing them and therapeutical composition containing these esters as active ingredients
  申请人：Newport Pharmaceuticals International, Inc.

  公开号：EP0036077A2

  公开（公告）日：1981-09-23

  There are prepared compounds of the formula where R1 is alkyl of 1 to 8 carbon atoms and R2 is the ester group of an unsubstituted monocarboxylic acid, aromatic carboxylic acid, aminocarboxylic acid, unsubstituted dicar. boxylic acid. phosphoric acid. or nitric acid or a glycoside or an acetaldehyde acetal The compounds are immunomodulators. have antiviral activity and antitumor activity and also are enzyme inhibitors. The compounds can also be used to introduce the corresponding alcohol into biological systems, in some cases with enhanced potency.

  制备了如下式的化合物 其中 R1 是 1 至 8 个碳原子的烷基，R2 是未取代的一羧酸、芳香族羧酸、氨基羧酸、未取代的二羧酸、磷酸或硝酸的酯基或苷或乙醛缩醛 这些化合物是免疫调节剂，具有抗病毒活性和抗肿瘤活性，也是酶抑制剂。这些化合物还可用于将相应的醇引入生物体系中，在某些情况下可增强其效力。
• Process for preparing imidazole compounds
  申请人：Newport Pharmaceuticals International, Inc.

  公开号：EP0126813A1

  公开（公告）日：1984-12-05

  There are prepared compounds of the formulae where R is a lower alkyl, chlorine, or bromine and n is an integer from 1 to 5. The compounds of formula (1) can be used to make erythro-9-(2-hydroxy-3-nonyl) hypoxanthine and its homologues and also to make the compounds of formulae (2) and (3). All three classes of compounds are useful as immunomodulators.

  制备的化合物式如下 其中 R 为低级烷基、氯或溴，n 为 1 至 5 的整数。式（1）化合物可用于制造红-9-（2-羟基-3-壬基）次黄嘌呤及其同系物，也可用于制造式（2）和（3）化合物。这三类化合物都可用作免疫调节剂。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• SIMON, NORTON;MUELLER, HANS-RUDOLF;ZUTTER, HANS
  作者：SIMON, NORTON、MUELLER, HANS-RUDOLF、ZUTTER, HANS

  DOI：——

  日期：——